FOLD stock news

Here are two rare disease biotech concerns worth a good look, as Alexion Pharmaceuticals is a solid company that is the subject of acquisition rumors and Amicus Therapeutics has a key drug off to a strong start….ALXN Read more
Amicus' (FOLD) earnings meet estimates in the second quarter while revenues beat the same. Read more
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 0.00% and 7.32%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock? Read more
Amicus' shares shot up by 10.7% last month. Here's why. Read more
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Read more
Earnings and other concerns held some stocks back Thursday. Read more
The company announced a significant stock offering. Read more

Microcaps tops midday movers

04:52pm, Thursday, 30'th May 2019
Read more

2 Ultra-High-Growth Biotech Stocks to Buy Now

02:34pm, Thursday, 30'th May 2019
Amicus Therapeutics and Array BioPharma are two top growth stocks to consider buying now. Read more
CRANBURY, N.J., May 10, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ: FOLD ) today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a fireside chat at the Bank of America Merrill Lynch 2019 Health Care Conference in Las Vegas, NV on Tuesday, May 14, 2019 at 1:00 p.m. PT. A live audio webcast of the … Full story available on Benzinga.com Read more

Proudly made at

ROCKIT